Report overview

The report presents Fuji Pharma's FY2019 consolidated net sales of JPY 36,279 Million and its shift toward a development-based pharmaceutical company through the Vision for 2030. It highlights women's healthcare products, biosimilars and global expansion from Toyama, alongside the LiLuLa women's health app. Sustainability activities include a President and CEO-chaired Sustainability Committee, energy-conservation work and education supporting female athletes.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018-2019
Period: 1 October 2018 – 30 September 2019
Language
Pages
File size

Standards & Assurance

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Report overview

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018-2019
Period: 1 October 2018 – 30 September 2019
Language
Pages
File size

Standards & Assurance

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services

Corporate Report

Report overview

Document

Standards & Assurance

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.

Corporate Report

Report overview

Document

Standards & Assurance

Assurance

ESG & Materiality

ESG data

Materiality

Build your research dataset.